36results about How to "Reduce collagen content" patented technology

An application of the Chinese medicine 'Superfine Tongxinluo' in relaxing the vascular endothelial injury caused by atherosclerosis, decreasing the cardiac infarction range after AMI reperfusion, preventing hyperlipemia and atherosclerosis, and treating arteria coronaria spasm, pile, thromboangiitis obliterans, platelet coagulation, etc is disclosed.

Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and/or increased myofibroblast content in tissue.

A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.

The invention discloses a human skin tissue endogenous polypeptide PDHPS1 and an application thereof. The amino acid sequence of the human skin tissue endogenous polypeptide PDHPS1 is shown in SEQ IDNO.1. The polypeptide PDHPS1 inhibits the propagation of a scar dermal fibroblast, inhibits the expression of mRNA of collagen genes COL1A1 and COL1A2 in the scar dermal fibroblast, and obviously reduces the protein expression of a main marker alpha-SMA of a myofibroblast in the scar dermal fibroblast. The human skin tissue endogenous polypeptide PDHPS1 can be used to prepare a drug or agent whichcan inhibit the propagation of the scar dermal fibroblast, reduce the collagen content and reduce the amount of the myofibroblast, and provides a new target spot for inhibiting the scar hypertrophy.

The invention belongs to the field of pharmacy, and relates to a new application of a compound GSK-J1 HCL to pharmacy, in particular to an application of a histone demethylase JMJD3 inhibitor GSK-J1 HCL to preparation of a medicine for treating myocardial fibrosis. Through an established myocardial fibrosis model caused by a mouse left coronary artery ligation operation and an Ang II induced NRCFs in-vitro myocardial fibrosis model experiment, a result shows that the GSK-J1 HCL has a regulation and control effect on myocardial fibrosis by inhibiting expression of JMJD3 to reduce collagen content and reducing expression of fibrosis related protein. The compound GSK-J1 HCL (C22H23N5O2.HCL) and the related inhibitor thereof can be used for preparing the medicine for preventing and treating myocardial fibrosis diseases.

The invention belongs to the technical field of medicine and particularly relates to a melatonin (MT) flexible liposome as well as a preparation method and application thereof. The MT flexible liposome is prepared from the following raw materials in parts by weight: 10-30 parts of MT, 70.00-90.00 parts of lecithin, 10-30 parts of cholesterol and 10-30 parts of sodium deoxycholate. The MT flexibleliposome has a better percutaneous permeation effect. Pharmacokinetic experiment results of rats show that the AUC of the flexible liposome is 1.82 times higher than that of ordinary liposome, indicating that the flexible liposome can improve the biocompatibility of percutaneous absorption of the MT. Pharmacodynamic experiment results of mice indicate that the external flexible liposome has an anti-photoaging effect. The flexible liposome enters a human body via skin and changes structures of stratum corneum lipid and keratin and can resist skin injury caused by ultraviolet sunburn.

The invention discloses a traditional Chinese medicine composition for treating hepatitis and liver cancer, comprising the following raw material medicines according to parts by weight: 1 to 120 parts of rhein or rhubarb class substances capable of being metabolized into the rhein in vivo, 1 to 50 parts of quercetin or quercetinic acid glucoside class substances capable of metabolized into the quercetinic acid in vivo and 3 to 60 parts of vinegar radix bupleuri, wherein the rhein is a market-sold product artificially synthesized or naturally extracted, and the purity is more than or equal to 80%. The composition can be prepared into various traditional Chinese medicine preparation medicines which can suppress the multiplication of liver cancer cells and promote the death of the liver cancer cells; an animal experiment validates that compared with the original anticancer medicine, the medicine can greatly enhance the concentration of the medicine in the liver and prolong the detention time of the medicine.

The invention discloses liver-nourishing food-made tea granules for preventing the alcohol liver, and belongs to the field of nutritional foods. The liver-nourishing food-made tea granulesare made of raw materials including carapace, peach kernel, ginseng leaves, fructus lycii, ligusticum wallichii and the like. The liver-nourishing food-made tea granules have the advantages of capacities of strengthening healthy energy and cultivating origin, reinforcing qi and nourishing blood, promoting blood circulation and dispersing blood stasis, preventing the alcohol liver, and being good and rapid in effect.

A Chinese medicine ''Gandening'' in the form of tablet, capsule, or particle for treating hepatitis B is prepared from 6 Chinese-medicinal materials including schisandra fruit, lucid ligustrum fruit, forsythia fruit, zedoary, etc. Its preparing process is also disclosed. Its advantage is high curative rate (82%).

The invention provides applications of a bilobalide composition in preparing medicines for preventing/treating chronic obstructive pulmonary diseases. The experiment proves that the bilobalide composition has the efficacies of improving the respiratory rate and pulmonary function of a model rat, reducing the expression of IFN-gamma and IL-6 of a model group rat, increasing the expression of IL-10of the model rat, increasing the number of pulmonary alveoli, reducing the content of collagen, and alleviating the airway remodeling in a dose-dependent manner, so that the effect of treating the chronic obstructive pulmonary diseases is achieved. Therefore, the bilobalide composition has the effect and application value of being prepared into medicines for preventing/treating the chronic obstructive pulmonary diseases.

The invention discloses a medicinal composition for treating chronic hepatopathy. The medicinal composition is composed of astragaloside and glycyrrhizic acid, and the weight ratio of astragaloside to glycyrrhizic acid is 3-6:1. Results of tests and verification through adopting a classic animal model show that the medicinal composition can substantially reduce the collagen content of the hepatic tissue of a model rat, mitigate the hepatic fibrosis degree and the hepatic damage degree, improve the hepatic fibrosis resistance, effectively prevent the development of the hepatic fibrosis and promote the reversion of the hepatic fibrosis, the above effects are better than effects realized through singly using the above components, and the medicinal composition can be used for treating and preventing various diseases comprising chronic hepatitis, hepatic fibrosis, hepatic cirrhosis and the like. The medicinal composition can be processed to prepare oral solid preparations comprising a tablet, a granule, a capsule and the like.

The invention provides a traditional Chinese medicine composition for treating pulmonary interstitial fibrosis. The traditional Chinese medicine composition is prepared from, by weight, 10-20 parts ofradix salviae miltiorrhizae, 4-8 parts of peach kernels, 2-4 parts of leeches, 5-15 parts of radix paeoniae rubra, 5-15 parts of radix ophiopogonis, 5-15 parts of fructus chebulae immaturus and 2-4 parts of semen oroxyli. A corresponding preparation method is adopted. The traditional Chinese medicine composition has the effect of treating the pulmonary interstitial fibrosis.